Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.70−0.06 (-1.60%)
Close on Nov 17, 2026Market cap $464.39MP/E –Yield –
Aquestive Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Aquestive Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 67.0%. For fiscal 2025 it was 58.3%, against 69.0% the year before. The highest annual figure on record is 71.7% in fiscal 2020.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 58.3% | −10.6 |
| FY2024 | Dec 31, 2024 | 69.0% | +10.1 |
| FY2023 | Dec 31, 2023 | 58.8% | −0.5 |
| FY2022 | Dec 31, 2022 | 59.3% | −12.4 |
| FY2020 | Dec 31, 2020 | 71.7% | +10.4 |
| FY2019 | Dec 31, 2019 | 61.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 70.9% | +16.5 |
| Q1 FY2026 | Mar 31, 2026 | 76.0% | +17.9 |
| Q4 FY2025 | Dec 31, 2025 | 55.2% | −6.8 |
| Q3 FY2025 | Sep 30, 2025 | 64.8% | −2.4 |
| Q2 FY2025 | Jun 30, 2025 | 54.4% | −23.1 |
| Q1 FY2025 | Mar 31, 2025 | 58.1% | −5.5 |
| Q4 FY2024 | Dec 31, 2024 | 61.9% | −2.7 |
| Q3 FY2024 | Sep 30, 2024 | 67.2% | +4.1 |
| Q2 FY2024 | Jun 30, 2024 | 77.5% | +27.5 |
| Q1 FY2024 | Mar 31, 2024 | 63.6% | +6.1 |
| Q4 FY2023 | Dec 31, 2023 | 64.6% | +14.2 |
| Q3 FY2023 | Sep 30, 2023 | 63.1% | +3.4 |
| Q2 FY2023 | Jun 30, 2023 | 50.0% | −10.5 |
| Q1 FY2023 | Mar 31, 2023 | 57.5% | −8.2 |
| Q4 FY2022 | Dec 31, 2022 | 50.3% | −16.5 |
| Q3 FY2022 | Sep 30, 2022 | 59.7% | −11.2 |
| Q2 FY2022 | Jun 30, 2022 | 60.5% | −14.7 |
| Q1 FY2022 | Mar 31, 2022 | 65.7% | +4.7 |
| Q3 FY2021 | Sep 30, 2021 | 66.9% | +2.9 |
| Q2 FY2021 | Jun 30, 2021 | 70.9% | −12.8 |
| Q1 FY2021 | Mar 31, 2021 | 75.2% | +17.0 |
| Q4 FY2020 | Dec 31, 2020 | 61.0% | +2.4 |
| Q3 FY2020 | Sep 30, 2020 | 63.9% | +1.3 |
| Q2 FY2020 | Jun 30, 2020 | 83.7% | +32.4 |
| Q1 FY2020 | Mar 31, 2020 | 58.3% | −14.0 |
| Q4 FY2019 | Dec 31, 2019 | 58.6% | – |
| Q3 FY2019 | Sep 30, 2019 | 62.6% | – |
| Q2 FY2019 | Jun 30, 2019 | 51.3% | – |
| Q1 FY2019 | Mar 31, 2019 | 72.3% | – |
See a number that looks wrong?